The utility of a CHA2DS2-VASc score in predicting the presence of significant stenosis and occlusion of veins with indwelling endocardial leads

被引:4
作者
Boczar, Krzysztof [1 ]
Zabek, Andrzej [1 ]
Debski, Maciej [1 ]
Haberka, Kazimierz [1 ]
Rydlewska, Anna [1 ]
Lelakowski, Jacek [1 ,2 ]
Malecka, Barbara [1 ,2 ]
机构
[1] John Paul 2 Hosp, Dept Electrocardiol, Pradnicka 80 St, PL-31202 Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Inst Cardiol, Krakow, Poland
关键词
CHA(2)DS(2)-VASc score; Venous stenosis; Venous occlusion; Phlebography; Pacemaker; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ATRIAL-FIBRILLATION; RISK STRATIFICATION; VENOUS THROMBOSIS; FOLLOW-UP; STROKE; THROMBOEMBOLISM; PACEMAKER; PREVALENCE; EXTRACTION;
D O I
10.1016/j.ijcard.2016.05.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Currently, there are no studies in which a CHA(2)DS(2)-VASc score has been used to predict the risk of venous stenosis and occlusion (VSO) in patients after the implantation of a cardiac implantable electronic device (CIED). Methods: The material consists of the records of 223 consecutive patients qualified for transvenous lead extraction, generator change and system revisions or upgrades in whom we assessed the utility of a CHA(2)DS(2)-VASc score in the prediction of VSO. The CHA(2)DS(2)-VASc score was calculated retrospectively based on the clinical data. The whole study population was divided into two groups, based on the presence (group I) or absence (group II) of VSO. Using the receiver operating characteristic (ROC) curve, we identified the optimal cut-off point for the CHA(2)DS(2)-VASc score that allowed the prediction of the absence of VSO. Results: The venography was performed in 223 consecutive patients aged on average 68.2years (25.7-95.3), 77 females (34.5%). The presence of VSO was detected in 79 (35.4%) patients aged 68.3 +/- 14.1 years, 30 female (40%) patients-group I. The level of the cut-off point for the CHA(2)DS(2)-VASc score that allowed the prediction of the absence of VSO was 3.0. Conclusion: In the whole population the incidence of VSO amounted to 35.4%. The result of the CHA(2)DS(2)-VASc score was a destimulant of VSO occurrence and was characterized by moderate sensitivity (73.4%) and specificity (42.4%) in predicting the absence of VSO. The most significant factor, which prevented VSO development was diabetes. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 50 条
  • [41] CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome
    Rozenbaum, Zach
    Elis, Avishay
    Shuvy, Mony
    Vorobeichik, Dina
    Shlomo, Nir
    Shlezinger, Meital
    Goldenberg, Ilan
    Kimhi, Oded
    Pereg, David
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 36 : 57 - 61
  • [42] Should we incorporate obstructive sleep apnea in CHA2DS2-VASc score?
    Christos Goudis
    Stylianos Daios
    Panagiotis Korantzopoulos
    Tong Liu
    Sleep and Breathing, 2021, 25 : 2099 - 2101
  • [43] Should we incorporate obstructive sleep apnea in CHA2DS2-VASc score?
    Goudis, Christos
    Daios, Stylianos
    Korantzopoulos, Panagiotis
    Liu, Tong
    SLEEP AND BREATHING, 2021, 25 (04) : 2099 - 2101
  • [44] Impact of the CHA2DS2-VASc score on late clinical outcomes in patients undergoing left atrial appendage occlusion
    Agudelo, Victor
    Millan, Xavier
    Li, Chi-Hion
    Asmarats, Lluis
    Fernandez-Peregrina, Estefania
    Santalo, Marcel
    Jimenez-Kockar, Marcelo
    Gheorghe, Livia
    Serra, Antonio
    Arzamendi, Dabit
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 319 : 78 - 84
  • [45] CHA2DS2-VASc is no longer enough
    Reiffel, James A.
    EUROPACE, 2022,
  • [46] CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis
    Philippart, Raphael
    Brunet-Bernard, Anne
    Clementy, Nicolas
    Bourguignon, Thierry
    Mirza, Alain
    Angoulvant, Denis
    Babuty, Dominique
    Lip, Gregory Y. H.
    Fauchier, Laurent
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (03) : 343 - 344
  • [47] Assessment of the CHA2DS2-VASc Score in Predicting Mortality and Adverse Cardiovascular Outcomes of Patients on Hemodialysis
    Pravda, Miri Schamroth
    Hagai, Keren Cohen
    Topaz, Guy
    Pravda, Nili Schamroth
    Makhoul, Nadeen
    Shuvy, Mony
    Benchetrit, Sydney
    Assali, Abid
    Pereg, David
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (08) : 635 - 640
  • [48] CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation
    Saliba, Walid
    Rennert, Gad
    AMERICAN JOURNAL OF MEDICINE, 2014, 127 (01) : 45 - 52
  • [49] Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA2DS2-VASc Score 1: A Nationwide Study
    Ostergaard, Lauge
    Olesen, Jonas Bjerring
    Petersen, Jeppe Kofoed
    Nielsen, Lukas Schak
    Kristensen, Soren Lund
    Schou, Morten
    Kober, Lars
    Fosbol, Emil
    CIRCULATION, 2024, 149 (10) : 764 - 773
  • [50] Mortality prediction with CHA2DS2-VASc, CHA2DS2-VASc-HS and R2CHA2DS2-VASc score in patients hospitalized due to COVID-19
    Katkat, F.
    Karahan, S.
    Varol, S.
    Kalyoncuoglu, M.
    Okuyan, E.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6767 - 6774